Key Highlights
- Beyond Air reported fiscal Q3 2026 Revenue of about $2.2 million, up roughly 105% year over year, with a net loss near $7.3 million.
- A binding letter of intent would see XTL Biopharmaceuticals acquire 85% of Beyond Air's NeuroNOS Subsidiary for up to $32.5 million.
- The company completed a private Placement of up to about $30.1 million in gross proceeds to fund its commercial launch and working capital.
Recovering a Nasdaq listing after a delisting scare is one thing; convincing the market that the reprieve is durable is another. Beyond Air, Inc, the nitric-oxide medical-device company trading under the ticker XAIR, has spent 2026 doing both, and its shares still trade in low single digits after a bruising stretch. A one-session decline of roughly 6% fits the profile of a small-cap that has raised fresh capital, restructured a subsidiary, and continued to burn cash while building out a commercial footprint for its lead product.
Company and Latest Development
Beyond Air is a commercial-stage company built around its LungFit platform, which generates nitric oxide from ambient air. Its lead product, LungFit PH, is cleared to treat term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Over recent quarters the company has expanded LungFit PH distribution internationally, adding agreements across markets including Canada, Germany, Brazil, Austria, the Netherlands and Sri Lanka, and reported its first sale to a U.S. Department of Veterans Affairs medical center. In late July 2026, Beyond Air announced a private placement of up to about $30.1 million in gross proceeds, priced at the market under Nasdaq rules, to fund Working Capital and the commercial launch of a second-generation LungFit PH.
What Is Driving Attention Around XAIR?
The roughly 5.9% drop flagged in the headline does not correspond to a single confirmed, same-session catalyst that can be independently verified. For a small-cap that recently completed an at-the-market-priced financing, day-to-day weakness can reflect dilution concerns, Warrant and pre-funded-warrant overhang, or general risk-off sentiment rather than fresh negative news. The broader attention around XAIR stems from its financing activity, its Nasdaq compliance history, and the gradual commercial ramp of LungFit PH.
Key Numbers and Company Position
Verified figures from Beyond Air's fiscal third quarter of 2026 (the quarter ended December 31, 2025) show revenue of about $2.2 million, up roughly 105% year over year, against a net loss near $7.3 million, or about $0.85 per share. The company reported pro forma cash of around $22.3 million, including net PIPE proceeds, and long-term Debt near $22.0 million, with management indicating a cash runway expected to extend into calendar 2027. Full-year fiscal 2026 revenue guidance was maintained at $8 million to $10 million. Separately, a binding letter of intent signed in January 2026 would see XTL Biopharmaceuticals acquire 85% of Beyond Air's NeuroNOS subsidiary, with Beyond Air eligible for up to $32.5 million in cash and milestones plus an Equity stake.
What Could Come Next?
Key catalysts include the commercial launch of the second-generation LungFit PH, which the filings indicate awaits FDA action on a PMA supplement, along with continued international distribution expansion and new hospital and VA placements. Delivery against the $8 million to $10 million revenue guidance, completion of the NeuroNOS transaction, and progress on early-stage programs such as LungFit for other indications would also matter. Financing and cash-runway updates remain central given the ongoing losses.
Risks to Watch
The principal risks are financial and executional. Continued net losses and reliance on external funding raise dilution risk, underscored by the recent private placement and outstanding warrants. Nasdaq listing compliance has been a live issue for the company. Commercialization risk, competition, reimbursement dynamics, and dependence on regulatory clearances for next-generation products round out the picture.
Conclusion
Beyond Air, Inc heads into late 2026 with rising revenue, a recently bolstered balance sheet, and a broader distribution network for LungFit PH, yet its shares remain volatile and under pressure. The near-6% decline appears to lack a discrete public catalyst and is best read against the company's financing overhang and cash-burn profile. Investors may be watching the second-generation LungFit PH launch, execution on revenue guidance, the NeuroNOS deal, and any fresh Nasdaq or funding updates as the developments most likely to steer sentiment.






Please wait processing your request...